Leflunomide Medac

Leflunomide, the active ingredient in Leflunomide Medac, is an immunomodulator presented as an oral tablet for oral use. It is used to treat rheumatoid arthritis and psoriatic arthritis in adult patients.

GNH USA supplies Leflunomide Medac as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease-modifying antirheumatic drug (DMARD) that targets inflammatory pathways in autoimmune arthritis. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: improves skin lesions and joint symptoms. - Active disease in adults: provides disease control when other DMARDs are insufficient.

Leflunomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, usually transient. - Hair loss: thinning of scalp hair. - Elevated liver enzymes: mild transaminase rise. - Rash: skin irritation or erythema. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe liver injury: potential for hepatitis or hepatic failure. - Aplastic anemia: profound bone‑marrow suppression. - Severe infections: increased susceptibility to opportunistic pathogens. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Stevens‑Johnson syndrome: severe skin reaction. - Teratogenicity: risk of fetal harm if exposure occurs during pregnancy.

Before initiating therapy, clinicians should assess baseline health and monitor patients regularly. - Monitor liver function: obtain baseline tests and repeat periodically. - Assess blood counts: watch for cytopenias, especially neutropenia. - Avoid in severe hepatic impairment: contraindicated in patients with existing liver disease. - Use effective contraception: teratogenic potential requires reliable birth control. - Discontinue before pregnancy: a wash‑out period of at least 8 weeks is recommended. - Store at ambient temperature: keep in the original pack, protect from moisture.

Leflunomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Teriflunomide: additive toxicity due to shared metabolic pathway. - Methotrexate: increased risk of hepatotoxicity. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise leflunomide plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Live vaccines: reduced efficacy, consider timing. - Azathioprine: additive bone‑marrow suppression, monitor blood counts. - Statins: possible increased risk of muscle toxicity, observe for myalgia.